MinervaX announces 72M EUR financing to advance development

/PRNewswire/ -- MinervaX ApS, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), today announces the...

Related Keywords

Germany , South Africa , Wellington , New Zealand General , New Zealand , Paris , France General , France , Denmark , Copenhagen , Køavn , United Kingdom , Danish , Veronica Gambillara , Pureos Bioventures , Christian Thomsen , Groupb Strep International , Groupb Streptococcus , Lund University , European Union , European Medicines Agency , Groupb Strep , Impact Fund Novo Holdings , European Investment Bank , Trill Impact Ventures , European Investment , Novo Holdings , Sunstone Life Science Ventures , Wellington Partners , Sanofi Ventures , Adjuvant Capital , Chief Executive Officer , Bita Sehat , Senior Director , Senior Investment Director , Life Science , Groupb Strep Support , Impact House , Trill Impact , Swiss Based Pureos Partners , Climate Bank Roadmap , Innovfin Infectious Diseases Finance Facility , Minervax ,